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A family history of disease is a strong risk factor for testicular germ cell tumour (TGCT). In order to identify
the location of putative TGCT susceptibility gene(s) we conducted a linkage search in 237 pedigrees with two
or more cases of TGCT. One hundred and seventy-nine pedigrees were evaluated genome-wide with an average
inter-marker distance of 10 cM. An additional 58 pedigrees were used to more intensively investigate several
genomic regions of interest. Genetic linkage analysis was performed with the ALLEGRO software using two
model-based parametric analyses and a non-parametric analysis. Six genomic regions on chromosomes
2p23, 3p12, 3q26, 12p13-q21, 18q21-q23 and Xq27 showed heterogeneity LOD (HLOD) scores of greater
than 1, with a maximum HLOD of 1.94 at 3q26. Genome-wide simulation studies indicate that the observed
number of HLOD peaks greater than one does not differ significantly from that expected by chance. A
TGCT locus at Xq27 has been previously reported. Of the 237 pedigrees examined in this study, 66 were pre-
viously unstudied at Xq27, no evidence for linkage to this region was observed in this new pedigree set.
Overall, the results indicate that no single major locus can account for the majority of the familial aggregation
of TGCT, and suggests that multiple susceptibility loci with weak effects contribute to the disease.
INTRODUCTION
Testicular germ cell tumour (TGCT) is the most common
cancer in men aged 15–45 years. Family history is one of
the strongest risk factors for the disease (1,2). Approximately,
2% of TGCT patients report an affected first degree relative.
The relative risk of TGCT to a brother of a case is increased
8–10-fold over the general population (1–3). This relative
risk among siblings is higher than that reported for most
other cancer types, which are typically two to four (4), and
suggests that genetic susceptibility is important in TGCT.
Support for a genetic component to TGCT is also provided
by the observation that the frequency of bilateral disease is
higher among cases with a family history than those without
(1,2). Further evidence is provided by a segregation analysis
based on Scandinavian TGCT patients. In this analysis, the
familial clustering observed in this series of pedigrees was
best explained by a single major gene with a recessive mode
of inheritance, an estimated gene frequency of 3.8% and a
life-time risk of developing TGCT of 43% among homozygote
men (5). A recessive model was also suggested by Nicholson
and Harland (6) who performed an analysis based on age at the
onset of TGCT and the frequency of bilateral disease.
The search for TGCT susceptibility genes has proven diffi-
cult. Large multiple generation pedigrees with many affected
individuals of the type which have been critical to identifying
the genes underlying hereditary breast, ovarian and colorectal
cancer are very rare for TGCT. The majority of TGCT pedi-
grees described in the literature are affected relative pairs,
predominantly siblings (1,2,7,8). As such families provide
relatively weak linkage information, large numbers of
pedigrees are required to achieve adequate power. In 1994,
an international collaboration, the International Testicular
Cancer Linkage Consortium (ITCLC), was established in
order to collect a sufficiently large set of multiple case families
for linkage studies. In 2000, using 134 pedigrees with two or
more cases of TGCT, 99 of which were compatible with
X-linkage, we published evidence for linkage of TGCT sus-
ceptibility to a locus at Xq27 (7). Among families with a
disease distribution compatible with X-linkage, the heterogen-
eity LOD (HLOD) was 2.01, rising to 4.7 among kindreds
containing at least one bilateral TGCT case. In 2003, we
reported a linkage analysis of 178 families, analysed for all
autosomes showing modest evidence for linkage to chromo-
some 12 (HLOD ¼ 2.05) (8). Here, we present the results of
an expanded linkage search using 237 TGCT kindreds and a
further evaluation of the putative Xq27 region.
RESULTS
The family set
A total of 459 pedigrees with DNA available from greater than
or equal to one affected case have been identified by the
ITCLC to date (Fig. 1A). Of these, 237 were considered to
be sufficiently well sampled to provide some linkage infor-
mation and were used in the analysis. The majority of pedi-
grees examined are affected sib pairs (Fig. 1B) and
approximately 10% of pedigrees examined have three or
more affected cases.
The 237 families examined in the linkage search included
518 patients with GCT. Forty-two patients from 38 families
had bilateral disease. Five patients had extragonadal GCT
only. A previous history of an undescended testis (UDT)
was recorded for 51 patients from 41 families. Of the 237 ped-
igrees examined, 163 (69%) were compatible with X-linked
mode of inheritance. Of these, 29 pedigrees had at least one
affected case with bilateral disease and 31 pedigrees had at
least one case with history of UDT. Histories of both UDT
and bilateral disease were reported among members of nine
pedigrees. In seven of these pedigrees, the bilateral case also
had UDT, whereas in two of these pedigrees the UDT status
of the bilateral case was unknown.
Genome-wide analysis
A total of 252 pedigrees were genotyped in this study. Prior to
inclusion in the linkage analysis the pedigree and genotyping
data was rigorously checked. The data integrity checks lead to
the exclusion of 15 pedigrees. Three of these pedigrees were
shown to be monozygotic twin pairs, eight were excluded
because DNA was derived from tumour material and the
sample failed to amplify consistently, and four demonstrated
inconsistent relationships which could not be resolved. After
the checks, a total of 237 pedigrees were available for
linkage analysis.
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Figure 1. (A) The ITCLC pedigree set by country, numbers beside country correspond to centre and author affiliation, grey bars show pedigrees ascertained by
the ITCLC for which a DNA sample from at least one affected case has been collected and submitted to the ITCLC for study. Black solid bars indicate pedigrees
examined in the linkage search. (B) The ITCLC set used in the current linkage analysis by pedigree structure, all relationships (unless stated) are for relative
pairs, half sibs–sibling with only one common parent; large–pedigrees with three or more cases, other than sib trios.
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A total of 179 pedigrees were examined genome-wide; 143
pedigrees were examined using the Applied Biosystems LMS-
MD10 microsatellite screening panel with marker spacing at
approximately 10 cM and 36 pedigrees were evaluated with
a 20 cM genome-wide marker map done at an earlier stage
of the genome-wide search.
Fifty-eight additional pedigrees for which sufficient material
was not available for a genome-wide search, or which were
ascertained after the primary genome-wide search was per-
formed were examined for regions of interest only. Previous
linkage reports (7,8) included data derived from a genome-
wide analysis published in 1995 (9). Genotyping for the
pedigree set studied in Leahy et al. was based on earlier tech-
nology, limited maps and markers. Furthermore, we were
unable to go back to original data to investigate any queries
generated in the data checking process. We therefore excluded
this early genotyping data from the current analysis. However,
we did later genotype the pedigree set studied in Leahy et al.
for regions of interest and this set makes up a substantial pro-
portion of the 58 pedigrees without genome-wide genotyping.
Regions of interest on chromosomes 3, 12 and 18 were
examined with a dense marker map (1–2 cM between adja-
cent markers) in 236 pedigrees. There was insufficient material
for extensive genotyping in one pedigree and this was geno-
typed for Xq27 only. All 237 pedigrees were genotyped for
the previously reported candidate region on Xq27, 66 of
these had not been examined at this region in previous
linkage searches. Table 1 gives a breakdown of the pedigree
set and the density of markers utilized in the analysis.
Statistical analysis
All marker loci were assessed for HWE and seven markers
were excluded on the basis of failure to meet this criterion.
A further 10 markers were removed because of poor or
limited genotyping data. Despite the exclusion of these
markers, the revised inter-marker distance for these regions
did not exceed 10 cM.
Genome-wide linkage analysis revealed no locus with a
statistically significant HLOD score greater than 3 under
either the dominant or recessive parametric model; or a
locus with a non-parametric linkage (NPL) LOD score
greater than 3. Six regions on chromosomes 2p23, 3p12,
3q26, 12p13-q21, 18q21-q23 and Xq27 showed HLOD
scores greater than 1.0 (Fig. 2, Table 2). The highest observed
HLOD was 1.94, a ¼ 0.27 on chromosome 3q26.
The two pre-specified data subgroups; pedigrees with at
least one case of bilateral disease and pedigrees with at least
one TGCT case with a history of UDT; were then analysed
for each region which showed an HLOD greater than 1.0 for
either inheritance model. The HLOD plots for the entire
data set, the bilateral subgroup and the UDT subgroup are
shown in Figure 3A–E. For the regions on chromosomes
2p23, 3p12, 3q26, and 18q21-q23 neither subgroup HLOD
exceeded that for the entire data set. The bilateral subgroup
showed a higher HLOD than the entire set for the regions
on chromosomes 12p13-q21 (HLOD ¼ 2.08; a ¼ 0.42, reces-
sive model) and Xq27 (HLOD ¼ 1.82; a ¼ 0.55), with the
region on chromosome 12 showing the highest HLOD score
observed. The UDT subgroup also showed a raised HLOD
on chromosome 12 (HLOD 1.66; a ¼ 0.35). No subgroup
demonstrated statistically significant HLOD scores.
Analysis of Xq27 region
The previously published analysis demonstrating linkage to
Xq27 was based on 99 pedigrees and generated an HLOD of
2.01, a ¼ 0.32 (7). The subset analysis of 15 pedigrees con-
sistent with X-linkage (no male-to-male transmission) and
with a history of bilateral TGCT demonstrated a statistically
significant result (HLOD ¼ 4.76; a ¼ 100%). Further details
of this subset, obtained subsequent to publication revealed
that one set of twins originally documented as dizygotic was
in fact shown to be monozygotic after a genome-wide
typing was performed, with all genotyping being identical.
A second pedigree in which one case was previously reported
to have had bilateral TGCT based on available medical
records was shown to be unilateral after the original pathology
reports were located and reviewed. This reduced our original
subset to 13 families with bilateral cases, which generated a
HLOD of 3.8, a ¼ 100%. In addition, a second X-compatible
family was demonstrated to be a monozygotic twin pair after
relationship testing and therefore the original set of 99
X-compatible pedigrees was reduced to 97.
The Xq27 region has now been examined in a further 66
pedigrees compatible with X-linked inheritance, including
16 new families with a bilateral case. The HLOD for this
new set in the Xq27 region is 0.02; a ¼ 0.03, with a HLOD
of 0.11, a ¼ 0.19 in the subset of bilateral cases. The total
number of pedigrees now analysed for linkage to Xq27 is
163 and the overall HLOD in this region is now 1.07,
a ¼ 0.18. The entire subset of bilateral families (n ¼ 29)
generated an HLOD of 1.82, a ¼ 0.55.
Exclusion mapping and simulations
For a model with a sibling relative risk of 8, all autosomal loci
generate a LOD score of less than 22 except for a 10 cM
region on chromosome 7 (55.40–66.47 Mb) which had an
exclusion LOD score of 21.3. For a sibling relative risk of
4, all regions of the autosomal genome were excluded with
a LOD score of less than 22 except for a 25 cM region on
chromosome 7 (48.57–75.29 Mb) and a 10 cM region on
chromosome 13 (57.00–62.15 Mb, where the LOD score
was between21.6 and22.0). However, there is no supportive
evidence from either the parametric or non-parametric analy-
sis in favour of linkage in either of these regions.
Table 1. Pedigrees examined in linkage search
Number of
pedigrees
10 cM genome-
wide map
20 cM genome-
wide map
Chromosomal regions
of interest
3, 12 and 18 Xq27
Genome-wide 143 36 179 179
Regions of interest 0 0 57 58
Total 143 36 236 237
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Two simulation studies were conducted to understand the
observed pattern of HLOD scores better. First, to determine
empirically the significance of observed linkage peaks, 100
simulations of marker genotypes under the null hypothesis
of no linkage were conducted. We examined the number of
peaks expected with a HLOD greater than 1.0, 2.0 and 3.0
and compared these to our observed data. A peak is defined
as a contiguous region (.1 cM) for which multipoint HLOD
scores exceed the defined critical value under either the domi-
nant or recessive model. Autosomal genome-wide simulations
under a null model identified on an average of 7.38 regions
with HLODs greater than or equal to 1.0, 0.70 regions with
HLODs greater than or equal to 2.0 and 0.05 regions with
HLODs greater than or equal to 3.0. We therefore observed
two HLOD peaks greater than or equal to 1.0 fewer than
would be expected by chance (excluding X).
Figure 2. HLOD plots for the genome-wide analysis. Multipoint linkage analyses are presented by chromosome (X-axis) as HLODs (values above zero) for
dominant (blue) and recessive (red) parametric models. Two HLOD peaks were identified on chromosome 3. Fig. 3B shows an expanded view of this chromo-
some demonstrating the two linkage peaks.
Table 2. HLOD scores greater than 1 for dominant and recessive models of inheritance
Chromosomal
location
Maximum HLOD
location (Mbp)
Region where
HLOD .1 (Mbp)
Markers defining
region
Dominant model Recessive model LOD score for model
with highest HLOD
NPL LOD
scoreMaximum
HLOD
a Maximum
HLOD
a
2p23 25.40 24.20–27.95 D2S171 1.14 0.18 0.46 0.09 219.79 (dominant) 0.22
3p12 102.05 79.83–102.05 D3S3681–D3S1271 1.11 0.20 0.14 0.05 215.33 (dominant) 0.22
3q26 164.89 156.34–171.96 D3S1607–D3S1282 1.94 0.27 0.12 0.05 215.31 (dominant) 1.42
12p13-q21 50.92 45.62–52.36 D12S85–D12S368 0.16 0.08 1.38 0.14 255.30 (recessive) 0.44
18q21-q23 65.59 60.87–70.28 D18S61–D18S58 0.25 0.09 1.44 0.12 259.19 (recessive) 0.85
Xq27 146.84 146.51–148.02 DXS548–DXS8091 0.81 0.17 1.04 0.17 250.57 (recessive) 0.88
The table contains the location in megabases for the region where the HLOD greater than 1, the point at which the HLOD maximized, the marker(s)
genotyped in the region, the HLOD score and the estimated proportion of families linked at this location (a) for both dominant and recessive models
and the LOD score assuming homogeneity of susceptibility for the model where the HLOD maximized. The table also contains the NPL LOD analysis
score for this location calculated using multipoint linkage analysis.
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The analyses conducted to date indicate that susceptibility is
likely to be heterogeneous (8,10). Simulating a dominant
model with all families linked to the disease locus produces
an expected HLOD of 19.48 with a ¼ 1.0, far exceeding
any observed HLOD. In the second of the simulation
studies, to inform the interpretation of the linkage analyses
under heterogeneity, we investigated the pattern of results
expected when the true model involves heterogeneity. We per-
formed simulations assuming 20 and 30% of our families were
linked to a disease locus (i.e. in keeping with the observed
estimated proportions of families linked). Under a dominant
model, these simulation show average HLODs of 0.54 and
Figure 3. HLOD plots for each chromosome demonstrating a HLOD greater than 1. Each figure shows a plot for the entire pedigree set (blue), the subgroup of
UDT pedigrees (yellow) and the subgroup of bilateral pedigrees (red). Approximate positions of markers defining region are shown. (A) Chromosome 2: domi-
nant model HLOD plot; (B) chromosome 3: dominant model HLOD plot; (C) chromosome 12, recessive model HLOD plot; (D) chromosome 18, recessive
model HLOD plot; (E) X chromosome, recessive model HLOD plot.
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1.2, respectively. The highest HLOD peak observed was on
chromosome 3q26, which under a dominant model achieves
a HLOD of 1.94, a ¼ 0.28. Therefore, under a dominant
model we observe peaks with HLODs marginally higher
than that we would expect by chance if only 30% of
the families were linked. Simulating a recessive model
with 20% and 30% of families linked gave HLOD scores of
1.14 and 2.73, respectively. The highest peak observed for a
recessive model was on chromosome 18 (HLOD ¼ 1.44;
a ¼ 0.12).
DISCUSSION
The genome-wide linkage analysis of this expanded set of
TGCT pedigrees found six genomic regions on chromosomes
2p23, 3p12, 3q26, 12p13-q21, 18q21-q23 and Xq27 with an
HLOD score greater than 1, but none of these achieved a
HLOD score of 2. Our simulation studies show that the
number of peaks observed is similar to that expected by
chance. Thus, while the observed peaks represent ‘regions of
interest’ that need to be pursued with additional pedigrees,
we cannot be confident that any harbour a TGCT susceptibility
locus. An important observation from the exclusion analyses is
that no locus is likely to explain a sibling relative risk of
4. Thus, results of these analyses suggest that several loci
must contribute to TGCT susceptibility, and that no one
locus explains a large fraction of the familial risk.
Critical to any linkage analyses is the number of pedigrees
available to be examined and a unique strength of this study is
the large number of pedigrees identified through the ITCLC
collaboration that includes all known groups worldwide with
an interest in familial TGCT. We have therefore been able
to conduct a much more powerful genome-wide search than
could have been achieved by any individual group. We have
taken considerable care to assess the integrity of the genotyp-
ing data and have excluded any marker or pedigree that fails
our rigorous series of quality control checks. We are therefore
confident that there are few errors in this data set. Despite the
size of the pedigree set available and given the genetic hetero-
geneity that the current analysis demonstrates, a much larger
series would be required to identify TGCT susceptibility
genes reliably by linkage analysis. Collection of TGCT pedi-
grees by the ITCLC is ongoing.
Increasing the density of the marker map could further
increase the power to detect linkage, but the gain may not
be great, as all data were examined by multipoint linkage
and any region of interest was examined using a denser
marker map. Furthermore, other than two small regions on
chromosomes 7 and 13, the exclusion mapping analysis did
not suggest regions where a finer marker map would make
an impact on the results. Hence, it is unlikely that any major
loci have been missed because of inadequate marker spacing.
The linkage evidence supporting a TGCT susceptibility
locus at Xq27 has weakened considerably in the expanded
family set. Typically, once a region of linkage for a specific
set has been identified, additional family sets are used to
either confirm or refute the published linkage results. The
rarity of TGCT in general and familial cases, in particular,
has meant that verification of the Xq27 locus could not be
attempted until a second confirmatory set was collected.
Ideally, a confirmatory set would be similar in number to
the original series and would come from the same population
base. We have now evaluated an additional 66 pedigrees com-
patible with X-linkage including an additional 16 new bilateral
TGCT pedigrees, which is a cohort comparable in size to the
original pedigree set. The analysis of the additional pedigree
set provided no evidence of linkage to this region and thus
this series of families provides no additional support for a
locus at Xq27. The potential for genetic heterogeneity across
populations exists, but the initial and additional pedigrees
come from similar populations, so this explanation appears
implausible. Analysis of the entire pedigree set compatible
with X-linkage still demonstrates a positive HLOD score for
Xq27, so a gene in this region cannot be completely excluded.
However, these data suggest that if such a gene in this region
does predispose to TGCT, it would account for only a small
proportion of TGCT susceptibility.
The original observation of linkage to Xq27 defined a
minimal region of interest from the subset of bilateral pedi-
grees (7). This minimal region at Xq27 contained three
genes, the FMR1 gene, a single exon gene Cxorf1 (10) and
a tandemly duplicated gene (LOC158813/158812). Prior to
the current linkage analysis, we had examined each of these
genes for small deletions, duplications and point mutations
by conformational gel electrophoresis (CSGE) (11) in the
series of X compatible families and found no evidence to
suggest that germline mutations in any of these genes contrib-
ute to TGCT (10).
The worldwide incidence of TGCT has doubled in the last
40 years (12–15). As this cannot be accounted for by the
genetic composition of a population, this trend suggests the
potential contribution of as yet unidentified environmental
factors in TGCT aetiology. Nonetheless, multiple studies
(1,5) support the notion that genetic factors are important for
TGCT. Our study suggests that susceptibility to TGCT is
determined through multiple loci. The probability of identify-
ing TGCT susceptibility genes will be enhanced by the collec-
tion of additional families via large consortia-based studies
such as the ITCLC; by more precise delineation of the syndro-
mic phenotypes of TGCT and by the utilization of advances in
genomic technology such as ultra-high throughput, high-
density SNP genotyping, which opens the way for genome-
wide SNP association studies.
MATERIALS AND METHODS
Families
Families with at least two cases of TGCT were identified by
collaborating groups worldwide and submitted to the ITCLC
for study. Patients donated samples and medical information
with full informed consent and under local or national
ethical review board approval. Information on clinical status,
including type of TGCT, age at diagnosis, the presence of
UDT and laterality of disease was confirmed by reviewing his-
tological reports and clinical notes. We required at least two
affected cases be sampled before genotyping was conducted
for a pedigree.
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Genotyping
Genomic DNA was prepared from whole blood, immortalized
lymphoblastoid cell lines or formalin-fixed, paraffin-embedded
tumour sections using standard techniques. The methodology
for genotyping has been described previously (7).
Statistical analysis
Data validation. Markers and individuals with limited genotyp-
ing on the basis of poor assay performance or sample quality
were excluded from further analysis. Non-Mendelian patterns
of marker inheritance were identified using PEDSTATS (16).
In rare instances of Mendelian errors the data were rechecked
and either corrected by re-scoring or set to missing within a
family if segregation could not be resolved. Hardy–Weinberg
Equilibrium (HWE) tests were performed on all markers, treat-
ing the data set as coming from a single population. Markers
found not to be in HWE (P, 0.01) were excluded from the
set. The order of the markers in our genome map was assessed
using MERLIN (16) to identify any unlikely recombination
events using the whole genome data. Any errors in the
genetic map were corrected with reference to published
sequence (http:/www.ensembl.org/Homo_sapiens/). Frequent
unlikely recombination events within families were interpreted
as possible pedigree structure or relationship errors.
The genetic relatedness of family members was tested to
identify any differences from the reported family structure.
For each relative pair the observed pattern of allele-sharing
for all markers was compared with that expected for the
reported relationship using GRR and PREST (17,18). We
excluded monozygotic twin pairs, corrected mis-specified
relationships where possible and excluded pedigrees in
which observed allele-sharing differed significantly from the
expected sharing and the inconsistency could not be resolved.
All families used in subsequent analyses described in this
paper passed these quality-control tests.
Linkage analysis. Genetic linkage analysis was performed
with the ALLEGRO (19) software using non-parametric and
two model-based parametric analyses, reflecting uncertainties
about the true underlying mode of inheritance. The parametric
linkage analysis inheritance models were based on the
described segregation analysis (5). A gene frequency of
0.003 and lifetime penetrance of 0.14 for a dominant model,
and a gene frequency of 0.03 and penetrance of 0.45 for
recessive model were assumed. As no formal segregation
analysis has fitted a sex-chromosome-linked model for
TGCT, the autosomal recessive model parameter values
were assumed for the X-chromosome model in this analysis.
Using these models, we computed multiple LOD scores at
every marker and at four inter-marker locations along the
genetic map of each chromosome. As multiple loci are
likely to be involved in susceptibility to TGCT, we compute
LOD scores under heterogeneity, assuming that a proportion
of families a was linked at the locus of interest, and maximiz-
ing HLOD at each position with respect to a. Analyses were
also conducted using the exponential allele-sharing model
(20) as implemented in ALLEGRO (19). Allele-sharing was
computed for each affected relative pair and equal weighting
given to each family.
In previous studies, we analysed families in a number of
pre-specified subgroups based on histology, UDT status, age
at cancer onset and bilaterality of cancer. For this analysis,
we limited the subgroups to bilaterality of cancer and
history of UDT. Previous analysis (7) showed that age at
cancer diagnosis and concordance for histology did not aggre-
gate within families and therefore we did not consider these
subgroups in this analysis. We examined subgroups only in
the regions where the maximum HLOD exceeded 1 for a par-
ticular genetic marker. Families were coded as bilateral if one
or more cases had either TGCT in both testes or TGCT in one
testis and carcinoma in situ (CIS) in the contralateral testis.
Patients with a documented extragonadal GCT and a sub-
sequent TGCT were not included in the bilateral series as it
was unclear if these were true multiple primaries or metastasis
from the same tumour (two cases only). Families were coded
as ‘UDT’ if at least one family member with TGCT also
reported a history of surgery for UDT (retractile testis or
hernia were not included in this subset). For analyses of
genetic markers on the X-chromosome, families were classi-
fied as ‘X-compatible’, if there was no evidence of male-to-
male transmission between the affected family members.
Map distances were estimated from base-pair distances
obtained from ENSEMBL and converted to genetic distances
assuming 1 Mbp to equal 1 cM. Where markers were not on
this map, positions were interpolated based on the position
of neighbouring markers on the Marshfield genetic map
(21). At each point, we computed the maximum HLOD
score assuming a completely informative marker, for the
whole data set and the subgroups, separately for the dominant
and recessive models used in the actual analysis.
To determine those regions unlikely to harbour suscepti-
bility loci, we performed exclusion mapping using GENE-
HUNTER (22). GENEHUNTER limits analysis to sibling
pairs, irrespective of other family members affected. In our
data set we have 134 sib pairs, nine sib trios, three half siblings
and 27 large pedigrees of which 17 include sibling pairs.
These 163 families are used to generate the exclusion values
for this part of the statistical analysis. LOD scores were com-
puted under the assumption of a sibling relative risk (lS) of
eight (corresponding to a single gene explaining all familial
aggregation) and a sibling relative risk of 4 (corresponding
to at least two genes explaining all familial aggregation) and
no genetic dominance (23). ‘Excluded’ regions were defined
as those with LOD less than 22.
Simulations were performed to assess the statistical signifi-
cance of the observed results. One hundred replicate data sets
were generated under the null hypothesis of no inherited sus-
ceptibility. These replicates were analysed using ALLEGRO
and the peak HLOD scores plus the number of peaks above
a HLOD score of 1.0, 2.0 and 3.0 were recorded. Each repli-
cate was analysed under both dominant and recessive models
of inheritance. Simulations were also performed using SLINK
under recessive and dominant models (i.e. the alternative
hypotheses) with varying proportions of linked families
to determine the expected peak HLODs and variation in the
estimated proportion of families linked at a single locus
(24,25).
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